Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 30, 2019
Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell CarcinomaMurtuza Bharmal, Matthias Hunger, Michael Schlichting
The Patient|June 30, 2022
Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13Cheryl D Coon, Michael Schlichting, Xinke Zhang
Applied Health Economics and Health Policy|December 14, 2020
What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death ApproachesAnthony J Hatswell, Ash Bullement, Michael Schlichting, et al.
Future Oncology (London, England)|November 6, 2019
Value assessment of immuno-oncology in the treatment of rare tumors in the era of accelerated conditional approvalsTereza Lanitis, Apoorva Ambavane, Ying Zheng, et al.
Health and Quality of Life Outcomes|May 21, 2020
Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinomaMurtuza Bharmal, Sandra Nolte, Mickaël Henry-Szatkowski, et al.
Future Oncology (London, England)|December 9, 2017
Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinomaHoward L Kaufman, Matthias Hunger, Meliessa Hennessy, et al.
Contemporary Clinical Trials Communications|November 17, 2022
Investigating the trends in patient-reported outcomes pre-treatment and implications to efficacy analyses: A post-hoc analysis of a cancer clinical trialMichael Schlichting, Hector Sanz, Paul Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximabSabine Tejpar, Ilhan Celik, Michael Schlichting, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 23, 2022
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) AddendumAntonia Morga, Nicholas R Latimer, Martin Scott, et al.
BMC Medical Research Methodology|May 8, 2020
Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selectionAsh Bullement, Anna Willis, Amerah Amin, et al.
Pageof 4